ArticleHepatology forum2022
Histopathological effects of Algan hemostatic agent (AHA) in liver injury model in rats.
Article in Hepatology forum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- Safety and hemostatic effect ofHepatology forum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: In this study, we aimed to assess the hemostatic and histopathological impacts of the Algan hemostatic agent (AHA) with the liver injury model. Materials and Methods: 24 male rats, 10-12 week old, were randomly divided into three equal groups (n=8) as control (physiological saline solution), AHA liquid and AHA powder. A total of three iatrogenic cut injuries were performed on the anterior surface of the left liver lobe. After bleeding started, sponges soaked with physiological saline, AHA liquid, AHA powder were gently pressed on the injured area for 20 seconds in corresponding groups, respectively. The bleeding time was measured with a timer. Failure to stop bleeding after three consecutive applications was considered as a failure. Animals were euthanized at the tenth minute of the procedure. Left liver lobes were removed for histopathological examination. Results: Bleeding control success rates of AHA liquid were significantly higher than that of the AHA powder group, and both forms were more effective than physiological saline. A superficial thick granulation tissue with entrapped powder residual materials was detected in the AHA powder group. Liver parenchyma was intact in liquid and powder groups. Conclusion: AHA is a fast-acting and applicable hemostatic agent in the liver bleeding model. However, further comparative studies in various organs are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.